Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Otonomy Inc (OTIC)

Otonomy Inc (OTIC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,167
  • Shares Outstanding, K 30,685
  • Annual Sales, $ 750 K
  • Annual Income, $ -50,370 K
  • 60-Month Beta 2.39
  • Price/Sales 105.85
  • Price/Cash Flow N/A
  • Price/Book 1.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.50
  • Number of Estimates 1
  • High Estimate -0.50
  • Low Estimate -0.50
  • Prior Year -0.44
  • Growth Rate Est. (year over year) -13.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.25 +13.78%
on 06/12/19
2.66 -3.76%
on 05/28/19
unch (unch)
since 05/24/19
3-Month
2.25 +13.78%
on 06/12/19
3.15 -18.86%
on 05/08/19
-0.19 (-6.91%)
since 03/22/19
52-Week
1.50 +70.67%
on 12/27/18
4.55 -43.74%
on 06/25/18
-1.64 (-39.05%)
since 06/22/18

Most Recent Stories

More News
Otonomy (OTIC) Reports Q1 Loss, Misses Revenue Estimates

Otonomy (OTIC) delivered earnings and revenue surprises of 15.22% and -40.92%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

OTIC : 2.56 (-0.78%)
Otonomy: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Otonomy Inc. (OTIC) on Monday reported a loss of $12 million in its first quarter.

OTIC : 2.56 (-0.78%)
Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update

-- OTIPRIO co-promotion agreement completed with Glenmark Therapeutics

OTIC : 2.56 (-0.78%)
Otonomy, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 6, 2019 / Otonomy, Inc. (NASDAQ: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 6, 2019 at 4:30 PM Eastern Time.

OTIC : 2.56 (-0.78%)
Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication

Glenmark Therapeutics Inc., USA, a wholly-owned subsidiary of Glenmark Holding SA., today announced a co-promotion agreement with Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to...

OTIC : 2.56 (-0.78%)
Otonomy Announces OTIPRIO(R) Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the signing of a co-promotion agreement with Glenmark...

OTIC : 2.56 (-0.78%)
Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the company will host one-on-one meetings with investors...

OTIC : 2.56 (-0.78%)
Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter...

OTIC : 2.56 (-0.78%)
Report: Developing Opportunities within Noble, Harris, Jazz Pharmaceuticals, Teradata, Abeona Therapeutics, and Otonomy -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Noble Corporation (NYSE:NE),...

TDC : 34.67 (+0.38%)
JAZZ : 131.31 (-2.28%)
ABEO : 4.43 (-4.11%)
NE : 1.65 (-2.94%)
HRS : 197.29 (+0.04%)
OTIC : 2.56 (-0.78%)
Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus

Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-313,...

OTIC : 2.56 (-0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade OTIC with:

Business Summary

Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner and middle ear disorders. The Company's product candidates under development includes AuriPro to treat pediatric patients with middle...

See More

Key Turning Points

2nd Resistance Point 2.61
1st Resistance Point 2.58
Last Price 2.56
1st Support Level 2.54
2nd Support Level 2.53

See More

52-Week High 4.55
Fibonacci 61.8% 3.38
Fibonacci 50% 3.03
Fibonacci 38.2% 2.67
Last Price 2.56
52-Week Low 1.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar